Cargando…
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757479/ https://www.ncbi.nlm.nih.gov/pubmed/35014603 http://dx.doi.org/10.1080/19420862.2021.2018960 |
_version_ | 1784632690356518912 |
---|---|
author | Yanakieva, Desislava Pekar, Lukas Evers, Andreas Fleischer, Markus Keller, Stephan Mueller-Pompalla, Dirk Toleikis, Lars Kolmar, Harald Zielonka, Stefan Krah, Simon |
author_facet | Yanakieva, Desislava Pekar, Lukas Evers, Andreas Fleischer, Markus Keller, Stephan Mueller-Pompalla, Dirk Toleikis, Lars Kolmar, Harald Zielonka, Stefan Krah, Simon |
author_sort | Yanakieva, Desislava |
collection | PubMed |
description | Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications. |
format | Online Article Text |
id | pubmed-8757479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-87574792022-01-14 Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities Yanakieva, Desislava Pekar, Lukas Evers, Andreas Fleischer, Markus Keller, Stephan Mueller-Pompalla, Dirk Toleikis, Lars Kolmar, Harald Zielonka, Stefan Krah, Simon MAbs Report Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications. Taylor & Francis 2022-01-11 /pmc/articles/PMC8757479/ /pubmed/35014603 http://dx.doi.org/10.1080/19420862.2021.2018960 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Yanakieva, Desislava Pekar, Lukas Evers, Andreas Fleischer, Markus Keller, Stephan Mueller-Pompalla, Dirk Toleikis, Lars Kolmar, Harald Zielonka, Stefan Krah, Simon Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title | Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title_full | Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title_fullStr | Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title_full_unstemmed | Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title_short | Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities |
title_sort | beyond bispecificity: controlled fab arm exchange for the generation of antibodies with multiple specificities |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757479/ https://www.ncbi.nlm.nih.gov/pubmed/35014603 http://dx.doi.org/10.1080/19420862.2021.2018960 |
work_keys_str_mv | AT yanakievadesislava beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT pekarlukas beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT eversandreas beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT fleischermarkus beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT kellerstephan beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT muellerpompalladirk beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT toleikislars beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT kolmarharald beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT zielonkastefan beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities AT krahsimon beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities |